The cornea is the clear window at the front of the eye and is the eye's main refractive medium. Its transparency is essential for vision. Corneal neovascularisation is a common clinical problem with serious consequences for vision; it can compromise corneal transparency and plays a major role in corneal graft rejection by breaching corneal immune privilege. In this review, we formulate a consensus on the unmet medical needs in the management of corneal neovascularisation and outline a framework for the clinical research that is needed to identify suitable agents to meet these needs.
- Corneal neovascularisation
- vascular endothelial growth factor
- clinical trials
- public health
- treatment medical
Statistics from Altmetric.com
This Roundtable was conducted during the 5–9 June 2010 World Ophthalmology Congress in Berlin, Germany.
Funding IZKF Erlangen (A9) and Voisin Consulting Life Sciences, France. The planning of this study, interpretation of findings, writing and conclusions of manuscript were undertaken entirely independently of the company interests.
Competing interests CC is a consultant to Gene Signal; all other authors except RD, LAF and DM received travel reimbursement and honoraria from Voisin Consulting Life Sciences, France.
Provenance and peer review Not commissioned; externally peer reviewed.